Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318344 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Atuna Racemosa Toxicity
A Phase 1 study of Bacterial Infections, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00318344: Completed Phase 1 study of Bacterial Infections, sponsored by Mayo Clinic.
NCT00318344 is a Phase 1 study of Bacterial Infections that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 140-participant average among 17 other Bacterial Infections trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318344, a Phase 1 study of Bacterial Infections, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibacterial properties. While this extract has been used for decades in the South Pacific, a controlled clinical trial to evaluate toxicity has never been performed.
Conditions Studied
Interventions
- DRUG Atuna Racemosa
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-11 |
| Phase | Phase 1 |
What the finished NCT00318344 record still lists
NCT00318344 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 140-participant average among 17 other Bacterial Infections trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Bacterial Infections appearing as the primary indexed condition, and to 1 intervention - of which Atuna Racemosa is the first listed.
NCT00318344 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00318344 about?
NCT00318344 is a clinical study titled "Evaluation of Atuna Racemosa Toxicity". For thousands of years people in the South Pacific have used Atuna racemosa extract as a topical anti-inflammatory. We, the researchers at the Mayo Clinic, have shown this extract to also have antibacterial properties. While this extract has been used for decades in the South Pacific, a controlled c...
What is the current status of trial NCT00318344?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-04. Estimated completion is 2007-11.
What conditions does trial NCT00318344 study?
This clinical trial studies the following conditions: Bacterial Infections.
What interventions are being tested in trial NCT00318344?
The interventions under investigation include: Atuna Racemosa (DRUG).
Who is sponsoring clinical trial NCT00318344?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00318344 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00318344's enrollment target sits among peer trials
20 16th of 17 higher than 1 of 17 other Bacterial Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacterial Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
RECRUITING · Phase 1
-
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
RECRUITING · Phase 1
-
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
COMPLETED · Phase 1
-
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
COMPLETED · Phase 1
-
A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia